Description du projet
Un dispositif pour traiter les complications consécutives à une chirurgie cardiaque
Après une chirurgie cardiaque, de nombreux patients développent une fibrillation auriculaire postopératoire (POAF), un type d’arythmie susceptible de multiplier le risque d’accident vasculaire cérébral par trois. Pour éviter le recours aux médicaments, le projet DefiPace-System, financé par l’UE, mettra sur le marché un dispositif qui facilitera la prévention et le traitement post‑opératoires de la POAF chez les patients. L’appareil aide le cœur à rétablir son rythme physiologique grâce à un processus appelé stimulation bi-auriculaire, et ce sans nécessiter d’anesthésie. Plus important encore, il s’agit d’un appareil portable, pratique et pouvant être utilisé par le personnel clinique général de n’importe quel hôpital.
Objectif
The incidence of cardiac surgeries is increasing world-wide in view of the demographic change. Cardiac surgery carries a
significant amount of risk as on average 60% of patients develop postoperative atrial fibrillation, by far the most frequently
occurring complication after cardiac surgery. Clinical investigations show a significant increase in morbidity, mortality and
duration of treatment and hospital stay. The risk for stroke is increased 3-fold! From all discussions with renowned surgeons
results the clear statement that an avoiding or reduction of medical drugs is in any circumstance a preferable and desirable
ambition. The DefiPace™ system is a proven and awaited method by the physicians treating post-operative patients. Our
new system is unique, as it is the only system in history and today, which allows physicians to prevent and terminate postoperative
atrial fibrillation (POAF) in all patients. It is the only system which combines standard stimulation, bi-atrial pacing
as well as epicardial low-energy cardioversion in one hand-held easy-to-use device even on general ward. Target customers
are all patients undergoing cardiac surgery world-wide (market volume: € 1.5 billion). Advantages: Simplicity • TMA pacing &
cardioversion wires: easy to use, similar to standard pacing wires • DefiPace device: Intuitive handling for clinical staff similar
to standard external pacemakers Prevention and Termination: • Bi-atrial pacing as an effective way to prevent POAF •
Quick Termination of atrial fibrillation with safe, elegant low energy cardioversion • No anesthesia necessary Cost savings
for surgical clinics • Significant cost savings: at least €1,000per day/patient Improved health • Few or no medication
required • All complications from atrial fibrillation can be completely avoided The DefiPace™-System is as a key product for
OSYPKA and will lead to significant increase of sales and employees. We will revolutionize the pacemaker market a second
time in our history
Champ scientifique
Programme(s)
Régime de financement
SME-2b - SME Instrument (grant only and blended finance)Coordinateur
79618 Rheinfelden Baden
Allemagne
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.